|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Assessing keloid recurrence following surgical excision and radiation显示文摘Keloids are a fibroproliferative disorder that can result from a cutaneous injury to the reticular dermis.Recurrence rates as high as 100%have been reported following surgical excision alone.Consequently,a variety of post-surgical techniques have been employed to prevent keloid recurrence,including the use of radiation.Although numerous studies have shown post-excisional X-rays,electron beam,lasers and brachytherapy can reduce the rate of keloid recurrence,numerous inconsistencies,including a wide range of definitions for keloid recurrence,make it difficult to compare study outcomes.The review aims to examine the various means for defining keloid recurrence in clinical trials involving the use of radiation therapy.Searches of the Cochrane Library and PubMed were performed to identify the available information for post-surgical keloid recurrence following radiation therapy.Each identified study was reviewed for patient followup and criteria used to define keloid recurrence.The search results included clinical studies with external beam radiation,brachytherapy and superficial radiation therapy.Many studies did not include a definition of keloid recurrence,or defined recurrence only as the return of scar tissue.Other studies defined keloid recurrence based on patient self-assessment questionnaires,symptoms and scar elevation and changes in Kyoto Scar Scale,Japan Scar Workshop Scale and Vancouver Scar Scale scores.The results of this review indicate keloidectomy followed by radiation therapy provide satisfactory recurrence rates;however,clinical studies evaluating these treatments do not describe treatment outcomes or use different definitions of keloid recurrence.Consequently,recurrence rates vary widely,making comparisons across studies difficult.Keloid recurrence should be clearly defined using both objective and subjective measures. | Michael H.Gold Mark S.Nestor Brian Berman David Goldberg | 2020 | Burns & Trauma2020，8，1： | 8 |
| 2 | Clinical laboratory and imaging evidence for effectiveness of agarose-agarose macrobeads containing stem-like cells derived from a mouse renal adenocarcinoma cell population (RMBs) in treatment-resistant, advanced metastatic colorectal cancer:Evaluation of显示文摘Objective: The complexity, heterogeneity and capacity of malignant neoplastic cells and tumors for rapid change and evolution suggest that living-cell-based biological-systems approaches to cancer treatment are merited. Testing this hypothesis, the tumor marker, metabolic activity, and overall survival(OS) responses, to the use of one such system, implantable macrobeads [RENCA macrobeads(RMBs)], in phase I and IIa clinical trials in advanced,treatment-resistant metastatic colorectal cancer(m CRC) are described here.Methods: Forty-eight m CRC patients(30 females; 18 males), who had failed all available, approved treatments,underwent RMB implantation(8 RMB/kg body weight) up to 4 times in phase I and phase IIa open-label trials.Physicals, labs [tumor and inflammation markers, lactate dehydrogenase(LDH)] and positron emission tomography-computed tomography(PET-CT) imaging to measure number/volume and metabolic activity of the tumors were performed pre-and 3-month-post-implantation to evaluate safety and initial efficacy(as defined by biological responses). PET-CT maximum standard uptake value(SUVmax)(baseline and d 90; SUVmax ≥2.5), LDH,and carcinoembryonic antigen(CEA) and/or cancer antigen 19-9(CA 19-9) response(baseline, d 30 and/or d 60)were assessed and compared to OS.Results: Responses after implantation were characterized by an at least 20% decrease in CEA and/or CA 19-9 in75% of patients. Fluorodeoxyglucose(FDG)-positive lesions(phase I, 39; 2 a, 82) were detected in 37/48 evaluable patients, with 35% stable volume and stable or decreased SUV(10) plus four with necrosis; 10, increased tumor volume, SUV. LDH levels remained stable and low in Responders(R)(d 0–60, 290.4–333.9), but increased steadily in Non-responders(NR)(d 0–60, 382.8–1,278.5)(d 60, P=0.050). Responders to RMBs, indicated by the changes in the above markers, correlated with OS(R mean OS=10.76 months; NR mean OS=4.9 months; P=0.0006).Conclusions: The correlations of the tumor marker, tumor volume and SUV changes on PET-CT, and LDH levels themselves, and with OS, support the concept of a biological response to RMB implantation and the validity of the biological-systems approach to m CRC. A phase III clinical trial is planned. | Barry H.Smith Lawrence S.Gazda Thomas J.Fahey Angelica Nazarian Melissa A.Laramore Prithy Martis Zoe P.Andrada Joanne Thomas Tapan Parikh Sudipta Sureshbabu Nathaniel Berman Allyson J.Ocean Richard D.Hall David J.Wolf | 2018 | Chinese Journal of Cancer Research2018，30，1： | 2 |
| 3 | An EOQ Model with State-dependent Demand Rate 显示文摘 | Oded Berman David Perry | 2006 | European Journal of Operational Research2006，171，1： | 1 |
| 4 | Outcome of a Workshop on Applications of Protein Models in Biomedical Research显示文摘 | Torsten Schwede Andrej Sali Barry Honig Michael Levitt Helen M. Berman David Jones Steven E. Brenner Stephen K. Burley Rhiju Das Nikolay V. Dokholyan Roland L. Dunbrack Krzysztof Fidelis Andras Fiser Adam Godzik Yuanpeng Janet Huang Christine Humblet Matt | 2009 | Structure2009，，2： | 1 |
| 5 | Microstaging of Breast Cancer Patients Using Cytokeratin Staining of the Sentinel Lymph Node显示文摘 | Robert H. Schreiber MD Solange Pendas MD Ni Ni Ku MD Douglas S. Reintgen MD Alan R. Shons MD PhD Claudia Berman MD David Boulware MS Charles E. Cox MD | 1999 | Annals of Surgical Oncology1999，，1： | 1 |
| 6 | Catabolite activator protein: DNA binding and transcription activation显示文摘 | Catherine L Lawson David Swigon Katsuhiko S Murakami Seth A Darst Helen M Berman Richard H Ebright | 2004 | Current Opinion in Structural Biology2004，，1： | 1 |
| 7 | Suppression of Ongoing Experimental Arthritis by a Chinese Herbal Formula (Huo-Luo-Xiao-Ling Dan) Involves Changes in Antigen-Induced Immunological and Biochemical Mediators of Inflammation显示文摘 | Ying-Hua Yang Rajesh Rajaiah David Y.-W Lee Zhongze Ma Hua Yu Harry H. S. Fong Lixing Lao Brian M. Berman Kamal D. Moudgil | 2010 | Evidence-Based Complementary and Alternative Medicine2010，，： | 1 |
| 8 | Applying the Freeman - Durden DeeompositionConcept to Polarimetric SAR Interferometry 显示文摘 | J DAVID B BERMAN JUAN M LOPEZ-SANCHEZ | 2010 | IEEE Trans- actions on Geoscience and Remotesensing2010，48，1： | 1 |
| 9 | Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy显示文摘 | Leslee J. Shaw Daniel S. Berman David J. Maron G B. John Mancini Sean W. Hayes Pamela M. Hartigan William S. Weintraub Robert A. O'Rourke Marcin Dada John A. Spertus Bernard R. Chaitman John Friedman Piotr Slomka Gary V. Heller Guido Germano Gilbert Gosse | 2008 | Circulation2008，，10： | 1 |
| 10 | Conservative management of cervical ectopic pregnancy: utility of uterine artery embolization显示文摘 | Mark A. Zakaria Mazen E. Abdallah Valerie I. Shavell Jay M. Berman Michael P. Diamond David C. Kmak | 2011 | Fertility and Sterility2011，，3： | 1 |
| 11 | Renal function after low central venous pressure‐assisted liver resection: assessment of 2116 cases显示文摘 | Camilo Correa‐Gallego Alexandra Berman Stephanie C. Denis Liana Langdon‐Embry David O’Connor Vittoria Arslan‐Carlon T. Peter Kingham Michael I. D’Angelica Peter J. Allen Yuman Fong Ronald P. DeMatteo William R. Jarnagin Jose Melendez Mary Fischer | 2015 | HPB2015，，3： | 1 |
| 12 | Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma显示文摘 | David Kleiner David Berman | 2012 | Digestive Diseases and Sciences2012，，8： | 1 |
| 13 | Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract turnouts 显示文摘 | David M Berman Sunil S karhadkar Anirban Maitra | 2003 | Nature2003，425，6960： | 1 |
| 14 | Rheolytic Thrombectomy With Percutaneous Coronary Intervention for Infarct Size Reduction in Acute Myocardial Infarction显示文摘 | Arshad Ali David Cox Nabil Dib Bruce Brodie Daniel Berman Navin Gupta Kevin Browne Robert Iwaoka Michael Azrin Dwight Stapleton Cindy Setum Jeffrey Popma | 2006 | Journal of the American College of Cardiology2006，，2： | 1 |
| 15 | Antitumoral effects of cannabis in Notch1-mutated T-cell acute lymphoblastic leukemia显示文摘Dear Editor,In T-cell acute lymphoblastic leukemia(T-ALL),an aggressive hematologic cancer with poor clinical outcomes,more than 50%of cases show NOTCH1-driven transformation[1].The NOTCH1 receptor signaling pathway is activated through a series of proteolytic cleavages,ultimately causing the release of the active intracellular domain(NICD),which translocates to the nucleus where it promotes transcription of target genes involved in cell growth.The importance of NOTCH1 mutations in T-ALL has generated great interest in the development of anti-NOTCH1 targeted therapies.A new and promising emerging field in cancer treatment is medical cannabis.Accumulating evidence suggests the direct effects of cannabis on tumor progression in cell lines and animal models[2].Cannabis,and its unique secondary metabolites,known as phytocannabinoids,directly affect the propagation of cancer cells by modulating key cellsignaling pathways[3].We have previously demonstrated that different cannabis extracts,each containing a unique composition of metabolites,selectively impaired the survival of cancer cell lines depending on amatch between the chemical composition of the extract and the characteristics of the specific cancer cell line[4].In the present work,we set out to investigate whether cannabis extracts with unique phytocannabinoid profiles can selectively facilitate antitumor effects in T-ALL cells that harbor a Notch1 mutation. | Elazar Besser Anat Gelfand Gil Moshe Lewitus Hila Novak-Kotzer Shiri Procaccia Paula Berman Igal Louria-Hayon Inbar Shreiber-Livne Yishai Ofran David Meiri | 2023 | Cancer Communications2023，43，6： | 0 |
| 16 | 我的选票去哪儿了?显示文摘曾经,每个美国人都对连孔票痛恨不已并对计算机投票心怀憧憬;在当时,这个主意听起来很靠谱 在去年10月孟菲斯举行市长及市政官员选举后的六天,当地一位 名为本尼·史密斯(Bermie Smith)的程序员下班后窝在自家沙发里查收电子邮件。孟菲斯是谢尔比县的首府,自从2006年当地官员决定改用电子投票机以来,选举总是技术事故频出。 | Michael Riley Jordan Robertson David Kocieniewski Julian Berman 微微 | 2016 | 商业周刊(中文版)2016，0，21： | 0 |
| 17 | 儿科补充与替代医学随机对照试验报告的质量评估显示文摘目的评估儿科补充与替代医学(Complementaryandalternativemedicine,CAM)随机对照试验报告的质量,检验报告质量是否随时间而变化。方法以包含251篇CAM干预的RCT报告作为系统样本,对每一篇报告质量用CONSORT清单的部分项目,如分配隐藏不清楚的比例和5级质量评价来进行评估。结果有近一半(40%)的CONSORT清单项目在所有RCT报告中列出,且有增多趋势。大多数RCT(81.3%)未清楚报告分配隐藏方案,且多年无改进。报告质量评分约为Jadad评估最高总评分的40%,且多年无改进。仅有约1/4(22%)的RCT报道了不良反应,而关于医疗成本的报道仅占很小比例(4%)。结论RCT是循证卫生保健决策的重要工具。如果这些研究要作为对CAM评估的一部分,那么高质量地实施和报告这些试验就显得十分重要。应加倍努力以确保儿童及其家庭进入实施和报告偏倚最小的RCT。这样的研究可以让利益共享者的范围更宽广,更具使用价值。 | David Moher Margaret Sampson Kaitryn Campbell William Beckner Leah Lepage Isabelle Caboury Brian Berman 张园 李芳 | 2005 | 中国循证医学杂志2005，5，5： | 0 |
| 18 | Role of nestin in glioma invasion显示文摘AIM: To determine the role for the intermediate filament protein nestin in glioma invasion. METHODS: We examined the expression and function of nestin in gliomas(Grades Ⅱ-Ⅳ as defined by the World Health Organization). We determined nestin expression using Immunohistochemical methods. To elucidate nestin's biological function(s), we reduced m RNA levels by 61% and 87% in two glioblastomaderived neurosphere lines using short hairpin RNAs and determined the effect of reduced nestin expression on glioma cell proliferation and invasion using MTS and matrigel migration assays, respectively. We also utilized quantitative real time polymerase chain reaction assaysto determine the effect of reduced nestin expression on the expression of other markers associated with glioma stem cells and their differentiated progenies. RESULTS: We found a significant correlation between nestin immunoreactivity and astrocytoma tumor grade, with 36% of grade Ⅱ, 75% of grade Ⅲ, and 100% of grade Ⅳtumors expressing significant levels of the protein when assessed using immunohistochemistry. Reduction in nestin expression had no effect on cell growth in culture, but did retard the capacity of one line to migrate in-vitro on matrigel. Interestingly, in the line whose migration was not affected, m RNA levels of a second intermediate filament, synemin(also knowns as desmuslin), were elevated following introduction of sh RNA targeting nestin. As synemin was not induced in the line which required nestin for migration, it is a possibility that synemin may compensate for the loss of nestin in this process. CONCLUSION: Nestin expression is prominent in high-grade astrocytomas. Nestin is not required for cell growth but it may, however, be required for cell motility. | Alex Lin Luigi Marchionni Jeffrey Sosnowski David Berman Charles G Eberhart Eli E Bar | 2015 | World Journal of Translational Medicine2015，4，3： | 0 |
| 19 | ERRα regulates the growth of triple-negative breast cancercells via S6K1-dependent mechanism显示文摘Estrogen-related receptor alpha(ERRα)is an orphan nuclear factor that is a master regulator of cellular energy metabolism.ERRαis overexpressed in a variety of tumors,including ovarian,prostate,colorectal,cervical and breast,and is associated with a more aggressive tumor and a worse outcome.In breast cancer,specifically,high ERRαexpression is associated with an increased rate of recurrence and a poor prognosis.Because of the common functions of ERRαand the mTORC1/S6K1 signaling pathway in regulation of cellular metabolism and breast cancer pathogenesis,we focused on investigating the biochemical relationship between ERRαand S6K1.We found that ERRαnegatively regulates S6K1 expression by directly binding to its promoter.Downregulation of ERRαexpression sensitized ERα-negative breast cancer cells to mTORC1/S6K1 inhibitors.Therefore,our results show that combinatorial inhibition of ERRαand mTORC1/S6K1 may have clinical utility in treatment of triple-negative breast cancer,and warrants further investigation. | Adi Y Berman Subrata Manna Naomi S Schwartz Yardena E Katz Yang Sun Catherine A Behrmann Jane J Yu David R Plas Anya Alayev Marina K Holz | 2017 | Signal Transduction and Targeted Therapy2017，2，1： | 0 |
| 20 | 行非紧急经皮冠状动脉介入治疗的患者使用SCH530348的安全性和耐受性:一项随机、双盲、安慰剂对照Ⅱ期研究显示文摘背景行经皮冠状动脉介入术(PCI)的患者需要抗血栓药物治疗,以安全地减少心血管事件的发生。、为此作者评价了患者使用SCH530348(一种口服的血小板蛋白酶激活受体l拮抗剂)的耐受性和安全性。方法在国际多中心研究中,将接受非紧急PCI或拟行PCI而行冠状动脉造影的患者(年龄≥45岁)以3:1的比例随机分配至口服负荷剂量SCH530348组.(10mg、20mg或40mg)或匹配的安慰刺组。SCH530348组中随后行PCI的患者(主要PCI队列)继续口服维持剂量(每天0.5mg、1.0mg或2.5mg),而安慰剂纽患者则继续服用安慰剂.共60d。主要终点是根据心肌梗死溶栓(TIMI)试验量表确定的有临床意义的大出血和少量出血。研究人员和患者均不知晓治疗分组情况。采用意向性治疗分析。本研究已在Clinical Trials.gov注册,注册号为NCT00132912。结果257例患者被分配至安慰剂组,773例患者被分配至SCH530348组,在SCH53034810mg、20mg和40mg组中,主要终点的发生率分别为2/129(3%)、3/120(3%)和7/173(7%).而安慰剂组中,主要终点的发生率为5/151(3%;P=0.5786)。在每天口服SCH530348O.5mg、1.0mg和2.5mg的患者中,TIMI大出血和少量出血的发生率分别为3/136(2%)、5/139(4%)和4/138(3%)(P=0.7651)。结论即使同时合并应用阿司匹林和氯吡格雷,患者仍能很好地耐受口服SCH530348,并且不导TIMI出血的增加。进一步验证以精确规定SCH530348的安全性和有效性的Ⅲ期临床试验已获得批准。 | Richard C Becker David J Moliterno Lisa K Jennings Karen S Pieper Jinglan Pei Alan Niederman Khaled M Ziada Gall Berman John Strony Diane Joseph Kenneth W Mahaff ey Frans Van de Were Enrico Veltri Robert A Harrington 徐景涛(译) | 2009 | 世界临床医学2009，，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员